Truist analyst Srikripa Devarakonda raised the firm’s price target on Incyte (INCY) to $79 from $73 and keeps a Hold rating on the shares after its Q2 earnings and revenue beat. Increased demand from Jakafi exceeded expectations, but the looming Jakafi loss of exclusivity remains a key overhang, and the firm remains on the sidelines for now, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte price target raised to $60 from $52 at BMO Capital
- Cautious Outlook on Incyte: Sell Rating Amid Long-Term Growth Concerns and Competitive Pressures
- Incyte price target raised to $68 from $62 at UBS
- Incyte price target raised to $103 from $88 at Citi
- Incyte’s Strong Q2 2025 Results and Strategic Advances